AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 271 min read$TWST

Leproust Emily M. sold $6.3M of TWST

Leproust Emily M. (Chief Executive Officer) sold 41,570 shares of Twist Bioscience Corp (TWST) at an average of $151.98 ($150.56–$154.45, $6.32M total) across 5 trades on 2026-08-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Leproust Emily M.
Published Aug 27, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TWST
Bearish
medium confidence
Mentioned
$TWST
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTBearishLow
01

Why it matters

The disclosed sale represents the first public notice of the transaction, making it a primary source of new information.

02

Market read

Insider sell of $6.3M may prompt short‑term price pressure; investors should monitor subsequent trading volume.

03

What to watch

CEO may be diversifying holdings; no immediate operational concerns indicated.

Relevance 5/10Novelty 7/10Timing: post-market 2026-08-25

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan pre‑arranges sales to avoid timing concerns.

Company-level read

Ticker impact

$TWSTBearishMedium confidence
Context

CEO Emily Leproust sold $6.3M of Twist Bioscience shares via a 10b5-1 plan on 2026-08-25.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

A $6.3M sale by the CEO is material and disclosed first via Form 4; markets often react negatively to insider sells of this size.

Market effects

Sector

May raise questions about biotech financing trends, but limited sector impact.

Regional

Primarily U.S. market; no broader regional effect.

Global

Minimal global relevance beyond Twist Bioscience investors.

Counterpoint

What could challenge this read

The sale could be a routine 10b5-1 execution unrelated to company outlook.

Key entities

  • Person
    Emily M. Leproust

    Chief Executive Officer of Twist Bioscience

  • Company
    Twist Bioscience Corp

    Biotechnology company listed on NASDAQ (TWST)

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TWST insider trading history →

Related articles

SEP 17
$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

timothysykes.com2 min
SEP 17
$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

timothysykes.com3 min
SEP 17
$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

stockstotrade.com3 min
SEP 17
$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.

timothysykes.com2 min